Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China

Authors: Xiao-chun He, Ning-ning Tao, Yao Liu, Xian-xin Zhang, Huai-chen Li

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Extensively Drug-Resistant (XDR) Tuberculosis (TB) has posed a great threat to global health and finance systems, especially for developing countries with high TB and Multidrug-Resistant (MDR) TB burden.

Methods

We retrospectively analyzed HIV-uninfected TB case confirmed and treated in Shandong Provincial Chest Hospital (SPCH) between January 2008 and December 2015. Unique characteristics of XDR-TB were identified; its longitudinal changes and survival were analyzed.

Results

Between January 2008 and December 2015, a total of 144 cases were confirmed to be XDR-TB (2.5% of 5663 culture-confirmed TB cases; 27.9% of 516 MDR-TB cases). The proportion of XDR TB cases among MDR-TB cases has increased from 26.5% in 2008 to 44.5% in 2014 (Chi-Square test for trends: P < 0.01). Among the 144 XDR-TB cases, 21 patients (14.6%) had treatment success, 123 (85.1%) had poor treatment outcomes. Mortality was higher among XDR-TB cases than among MDR TB cases (8.3% vs. 3.8%, P = 0.033) and drug-susceptible TB cases (8.3% vs. 2.1%, P < 0.01).

Conclusions

XDR-TB cases comprise a substantial and increasing fraction of MDR-TB cases, causing poor treatment outcomes and high mortalities. Early drug susceptibility testing, adequate TB treatment and efficient infection control must be in place in future TB control strategies.
Literature
2.
go back to reference Raviglione MC, Smith IM. XDR tuberculosis—implications for global public health. N Engl J Med. 2007;356:656–9.CrossRefPubMed Raviglione MC, Smith IM. XDR tuberculosis—implications for global public health. N Engl J Med. 2007;356:656–9.CrossRefPubMed
3.
go back to reference Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80.CrossRefPubMed Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575–80.CrossRefPubMed
4.
go back to reference Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55:301–5. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 2006;55:301–5.
5.
go back to reference Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45:1409–14.CrossRefPubMed Pillay M, Sturm AW. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin Infect Dis. 2007;45:1409–14.CrossRefPubMed
6.
go back to reference Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42–9.CrossRefPubMed Jeon CY, Hwang SH, Min JH, et al. Extensively drug-resistant tuberculosis in South Korea: risk factors and treatment outcomes among patients at a tertiary referral hospital. Clin Infect Dis. 2008;46:42–9.CrossRefPubMed
7.
go back to reference Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistant acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63.CrossRefPubMedPubMedCentral Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistant acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59:1049–63.CrossRefPubMedPubMedCentral
8.
go back to reference Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRefPubMed Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798–807.CrossRefPubMed
9.
go back to reference O’Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153:516–22.CrossRefPubMedPubMedCentral O’Donnell MR, Jarand J, Loveday M, et al. High incidence of hospital admissions with multidrug-resistant and extensively drug-resistant tuberculosis among South African health care workers. Ann Intern Med. 2010;153:516–22.CrossRefPubMedPubMedCentral
10.
go back to reference Gandhi NR, Weissman D, Moodley P, et al. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. J Infect Dis. 2013;207:9–17.CrossRefPubMed Gandhi NR, Weissman D, Moodley P, et al. Nosocomial Transmission of Extensively Drug-Resistant Tuberculosis in a Rural Hospital in South Africa. J Infect Dis. 2013;207:9–17.CrossRefPubMed
11.
go back to reference Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290–5.CrossRefPubMed Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45:1290–5.CrossRefPubMed
12.
go back to reference Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31:1155–9.CrossRefPubMed Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31:1155–9.CrossRefPubMed
13.
go back to reference Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively Drug-Resistant Tuberculosis in the United States, 1993–2007. JAMA. 2008;300:2153–60.CrossRefPubMed Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP. Extensively Drug-Resistant Tuberculosis in the United States, 1993–2007. JAMA. 2008;300:2153–60.CrossRefPubMed
14.
go back to reference Marks UM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20:812–21.CrossRefPubMedPubMedCentral Marks UM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005–2007. Emerg Infect Dis. 2014;20:812–21.CrossRefPubMedPubMedCentral
16.
go back to reference Zhao YL, Xu SF, Wang LX, et al. National Survey of Drug-Resistant Tuberculosis in China. N Engl J Med. 2012;366:2161–70.CrossRefPubMed Zhao YL, Xu SF, Wang LX, et al. National Survey of Drug-Resistant Tuberculosis in China. N Engl J Med. 2012;366:2161–70.CrossRefPubMed
18.
go back to reference Tang S, Tan S, Yao L, et al. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. PLoS One. 2013;8:e82943.CrossRefPubMedPubMedCentral Tang S, Tan S, Yao L, et al. Risk Factors for Poor Treatment Outcomes in Patients with MDR-TB and XDR-TB in China: Retrospective Multi-Center Investigation. PLoS One. 2013;8:e82943.CrossRefPubMedPubMedCentral
20.
go back to reference World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (fourth edition). Geneva: WHO; 2009. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis (fourth edition). Geneva: WHO; 2009.
21.
go back to reference World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO Press; 2014. WHO/HTM/TB/2014.11. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: WHO Press; 2014. WHO/HTM/TB/2014.11.
22.
go back to reference Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.PubMed Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, et al. Speaking the same language: treatment outcome definitions for multidrugresistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640–5.PubMed
23.
go back to reference Sun Z, Chao Y, Zhang X, et al. Characterization of extensively drug-resistant mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:4075–7.CrossRefPubMedPubMedCentral Sun Z, Chao Y, Zhang X, et al. Characterization of extensively drug-resistant mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:4075–7.CrossRefPubMedPubMedCentral
24.
go back to reference Qi YC, Ma MJ, Li DJ, et al. Multidrug-resistant and extensively drug-resistant tuberculosis in multi-ethnic region, Xinjiang Uygur Autonomous Region, China. PLoS One. 2012;7:e32103.CrossRefPubMedPubMedCentral Qi YC, Ma MJ, Li DJ, et al. Multidrug-resistant and extensively drug-resistant tuberculosis in multi-ethnic region, Xinjiang Uygur Autonomous Region, China. PLoS One. 2012;7:e32103.CrossRefPubMedPubMedCentral
25.
go back to reference National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Implementing Office of the Epidemiological Sampling Survey for Tuberculosis. The prevalence of pulmonary tuberculosis in a national survey across China in 2010. Zhong hua Jie He He Hu Xi Za Zhi. 2012;35:665–8. National Technical Steering Group of the Epidemiological Sampling Survey for Tuberculosis, Implementing Office of the Epidemiological Sampling Survey for Tuberculosis. The prevalence of pulmonary tuberculosis in a national survey across China in 2010. Zhong hua Jie He He Hu Xi Za Zhi. 2012;35:665–8.
30.
go back to reference Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–6.CrossRefPubMed Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010;181:80–6.CrossRefPubMed
31.
go back to reference Zhong NS, Wang C, Yao WC, Chen P, Kang J, Huang SG, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.CrossRefPubMed Zhong NS, Wang C, Yao WC, Chen P, Kang J, Huang SG, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:753–60.CrossRefPubMed
32.
go back to reference Inghammar M, Ekbom A, Engström G, Ljungberg B, Romanus V, Lofdahl CG, et al. COPD and the risk of tuberculosis: A population-based cohort study. PLoS One. 2010;5:e10138.CrossRefPubMedPubMedCentral Inghammar M, Ekbom A, Engström G, Ljungberg B, Romanus V, Lofdahl CG, et al. COPD and the risk of tuberculosis: A population-based cohort study. PLoS One. 2010;5:e10138.CrossRefPubMedPubMedCentral
33.
go back to reference Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of tuberculosis in patients with chronic obstructive pulmonary disease. Chest. 2013;143:1018–24.CrossRefPubMed Kim JH, Park JS, Kim KH, Jeong HC, Kim EK, Lee JH. Inhaled corticosteroid is associated with an increased risk of tuberculosis in patients with chronic obstructive pulmonary disease. Chest. 2013;143:1018–24.CrossRefPubMed
34.
go back to reference LimS LDC, Muttalif AR, Yunus F, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4.CrossRef LimS LDC, Muttalif AR, Yunus F, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4.CrossRef
35.
go back to reference Gaude GS, Rajesh BP, Chaudhury A, et al. Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization. Lung India. 2015;32:465–72.CrossRefPubMedPubMedCentral Gaude GS, Rajesh BP, Chaudhury A, et al. Outcomes associated with acute exacerbations of chronic obstructive pulmonary disorder requiring hospitalization. Lung India. 2015;32:465–72.CrossRefPubMedPubMedCentral
37.
go back to reference Hasegawa W, Yamauchi Y, Yasunaga H, et al. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:151.CrossRefPubMedPubMedCentral Hasegawa W, Yamauchi Y, Yasunaga H, et al. Factors affecting mortality following emergency admission for chronic obstructive pulmonary disease. BMC Pulm Med. 2014;14:151.CrossRefPubMedPubMedCentral
39.
go back to reference Liu CH, Yang N, Wang Q, Hu YL, Li L, Zhang GY, et al. Risk factors associated with fluoroquinolone resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology. 2011;16:918–25.CrossRefPubMed Liu CH, Yang N, Wang Q, Hu YL, Li L, Zhang GY, et al. Risk factors associated with fluoroquinolone resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology. 2011;16:918–25.CrossRefPubMed
Metadata
Title
Epidemiological trends and outcomes of extensively drug-resistant tuberculosis in Shandong, China
Authors
Xiao-chun He
Ning-ning Tao
Yao Liu
Xian-xin Zhang
Huai-chen Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2652-x

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue